Science Corp Implants Vision Chip in First Stargardt Patient
Science Corp implants its vision‑restoring chip in a Stargardt disease patient, a milestone for its PRIMA brain‑computer interface program.
Science Corporation announced the implantation of its vision‑restoring chip in a patient diagnosed with Stargardt disease, marking the company’s first clinical use of the technology. The procedure was performed as part of the company’s PRIMA program, which aims to develop advanced neural interfaces.
Max Hodak, the former president and co‑founder of Neuralink, presented the milestone at TechCrunch Disrupt, explaining that the Stargardt case is a stepping stone toward a broader brain‑computer interface (BCI) platform. Hodak said the implant demonstrates how the PRIMA system can translate visual signals directly to the brain, potentially restoring sight for degenerative eye conditions.
The company emphasized that the successful implantation validates its approach to integrating electronic devices with neural tissue, and it plans to expand trials to additional patients while refining the BCI technology for future applications.
Why It Matters
Restoring vision for degenerative eye diseases could impact millions, and the underlying BCI technology may have broader neurological applications in the US and Europe.
More in Tech
Justice Dept. Says North Korean Hackers Infiltrated Dozens of U.S. Firms
Cerebras CEO Says Personal AI Assistants Will Soon Be Commonplace
Tech